Detail akcie Kazia Sp ADR online

Business Summary: Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Kazia Therapeutics Ltd (ADR) revenues decreased 95% to A$114K. Net loss decreased 23% to A$20.7M. Revenues reflect Revenue decrease of 98% to A$42K. Lower net loss reflects Research and development expense - Balan decrease of 65% to A$4.5M (expense), Loss on revaluation of contingent consid increase from A$119K to A$7.6M (income).